Medicenna Therapeutics Analyst Ratings
Medicenna Therapeutics Analyst Ratings
While ratings are subjective and will change, the latest Medicenna Therapeutics (MDNA) rating was a maintained with a price target of $5.00 to $4.00. The current price Medicenna Therapeutics (MDNA) is trading at is $0.98, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/16/2022 | 308.16% | HC Wainwright & Co. | $5 → $4 | Maintains | Buy |
| 06/23/2022 | 920.41% | Oppenheimer | $12 → $10 | Maintains | Outperform |
| 06/23/2022 | 410.2% | HC Wainwright & Co. | $7 → $5 | Maintains | Buy |
| 06/01/2021 | 614.29% | HC Wainwright & Co. | $8 → $7 | Maintains | Buy |
| 12/18/2020 | 1124.49% | Oppenheimer | → $12 | Initiates Coverage On | → Outperform |
| 12/17/2020 | 1124.49% | Oppenheimer | → $12 | Initiates Coverage On | → Outperform |
| 09/10/2020 | 716.33% | HC Wainwright & Co. | → $8 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/16/2022 | 308.16% | HC Wainwright & Co. | 5 美元 → 4 美元 | 维护 | 买 |
| 06/23/2022 | 920.41% | 奥本海默 | 12 美元 → 10 美元 | 维护 | 跑赢大盘 |
| 06/23/2022 | 410.2% | HC Wainwright & Co. | 7 美元 → 5 美元 | 维护 | 买 |
| 06/01/2021 | 614.29% | HC Wainwright & Co. | 8 美元 → 7 美元 | 维护 | 买 |
| 2020 年 12 月 18 日 | 1124.49% | 奥本海默 | → 12 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 2020 年 12 月 17 日 | 1124.49% | 奥本海默 | → 12 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 2020 年 10 月 9 日 | 716.33% | HC Wainwright & Co. | → 8 美元 | 启动覆盖范围开启 | → 购买 |
Medicenna Therapeutics Questions & Answers
Medicenna Therapeutics 问题与解答
The latest price target for Medicenna Therapeutics (NASDAQ: MDNA) was reported by HC Wainwright & Co. on August 16, 2022. The analyst firm set a price target for $4.00 expecting MDNA to rise to within 12 months (a possible 308.16% upside). 3 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2022年8月16日公布了Medicenna Therapeutics（纳斯达克股票代码：MDNA）的最新目标股价。该分析公司将目标股价定为4.00美元，预计MDNA将在12个月内升至12个月内（可能上涨308.16％）。去年有3家分析公司公布了评级。
The latest analyst rating for Medicenna Therapeutics (NASDAQ: MDNA) was provided by HC Wainwright & Co., and Medicenna Therapeutics maintained their buy rating.
Medicenna Therapeutics（纳斯达克股票代码：MDNA）的最新分析师评级由HC Wainwright & Co. 提供，Medicenna Therapeutics维持买入评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Medicenna Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Medicenna Therapeutics was filed on August 16, 2022 so you should expect the next rating to be made available sometime around August 16, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Medicenna Therapeutics的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Medicenna Therapeutics的最新评级是在2022年8月16日发布的，因此您应该预计下一个评级将在2023年8月16日左右公布。
While ratings are subjective and will change, the latest Medicenna Therapeutics (MDNA) rating was a maintained with a price target of $5.00 to $4.00. The current price Medicenna Therapeutics (MDNA) is trading at is $0.98, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Medicenna Therapeutics（MDNA）评级维持不变，目标股价为5.00美元至4.00美元。Medicenna Therapeutics（MDNA）目前的交易价格为0.98美元，超出了分析师的预期区间。
